AMBER SHULL: Open Payments
NPI 1770546749 · NORTON SHORES, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$38,223 in 224 payments from 28 companies in 2025. Trend: 2023 $43,852 · 2024 $46,445 · 2025 $38,223
Speaker / faculty: $28,402Food & beverage: $4,019Consulting: $3,460Travel & lodging: $2,342
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 41 | $13,623 |
| Teva Pharmaceuticals USA, Inc. | 34 | $12,382 |
| ABBVIE INC. | 38 | $5,712 |
| Otsuka America Pharmaceutical, Inc. | 12 | $3,634 |
| E.R. Squibb & Sons, L.L.C. | 9 | $1,014 |
| Supernus Pharmaceuticals, Inc. | 26 | $506 |
| Alkermes, Inc. | 9 | $203 |
| Axsome Therapeutics, Inc. | 7 | $188 |
| Vanda Pharmaceuticals Inc. | 8 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $102 |
Products named: CAPLYTA, AUSTEDO XR, VRAYLAR, REXULTI, Qelbree, COBENFY, LINZESS, ARISTADA.
Industry payments across MI — which companies pay providers there.
